JP2018526428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526428A5 JP2018526428A5 JP2018513549A JP2018513549A JP2018526428A5 JP 2018526428 A5 JP2018526428 A5 JP 2018526428A5 JP 2018513549 A JP2018513549 A JP 2018513549A JP 2018513549 A JP2018513549 A JP 2018513549A JP 2018526428 A5 JP2018526428 A5 JP 2018526428A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- effector
- patient
- virus
- oncolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 244000309459 oncolytic virus Species 0.000 claims 35
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 230000001419 dependent effect Effects 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 230000002519 immonomodulatory effect Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 238000002255 vaccination Methods 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000002927 anti-mitotic effect Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001372913 Maraba virus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003145 cytotoxic factor Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 108010072285 growth inhibitory proteins Proteins 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147640A JP2022003043A (ja) | 2015-09-09 | 2021-09-10 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
| JP2023176751A JP2023176003A (ja) | 2015-09-09 | 2023-10-12 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216046P | 2015-09-09 | 2015-09-09 | |
| US201562216062P | 2015-09-09 | 2015-09-09 | |
| US62/216,062 | 2015-09-09 | ||
| US62/216,046 | 2015-09-09 | ||
| US201562255294P | 2015-11-13 | 2015-11-13 | |
| US62/255,294 | 2015-11-13 | ||
| US201662323065P | 2016-04-15 | 2016-04-15 | |
| US62/323,065 | 2016-04-15 | ||
| PCT/US2016/050994 WO2017044780A1 (en) | 2015-09-09 | 2016-09-09 | Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147640A Division JP2022003043A (ja) | 2015-09-09 | 2021-09-10 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526428A JP2018526428A (ja) | 2018-09-13 |
| JP2018526428A5 true JP2018526428A5 (enExample) | 2019-10-24 |
Family
ID=58240173
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513549A Withdrawn JP2018526428A (ja) | 2015-09-09 | 2016-09-09 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
| JP2021147640A Pending JP2022003043A (ja) | 2015-09-09 | 2021-09-10 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
| JP2023176751A Pending JP2023176003A (ja) | 2015-09-09 | 2023-10-12 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147640A Pending JP2022003043A (ja) | 2015-09-09 | 2021-09-10 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
| JP2023176751A Pending JP2023176003A (ja) | 2015-09-09 | 2023-10-12 | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20190038727A1 (enExample) |
| EP (1) | EP3347473A4 (enExample) |
| JP (3) | JP2018526428A (enExample) |
| WO (1) | WO2017044780A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8052968B2 (en) | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| EP3261669B1 (en) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
| EP3347473A4 (en) * | 2015-09-09 | 2019-04-10 | Tvax Biomedical I, LLC | METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| WO2017147553A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| EP4197551A3 (en) | 2016-06-24 | 2023-10-25 | McMaster University | Adoptive cell transfer and oncolytic virus combination therapy |
| EP3577132A4 (en) | 2017-02-03 | 2021-03-10 | University of Pittsburgh - of The Commonwealth System of Higher Education | ONCOLYTIC VIRUS THERAPY |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| US20220347244A1 (en) * | 2018-01-19 | 2022-11-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| AU2019339535B2 (en) | 2018-09-15 | 2025-11-20 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| EP3897846A1 (en) * | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| WO2020186355A1 (en) * | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Sequential heterologous boost oncolytic viral mmunotherapy |
| WO2020247547A1 (en) * | 2019-06-03 | 2020-12-10 | Geovax, Inc. | Cancer vaccine compositions and methods for use thereof |
| BR112021022112A2 (pt) * | 2019-06-05 | 2022-01-04 | Laitram Llc | Transportador espiral, correia transportadora espiral, e módulo de correia transportadora |
| CN110540960A (zh) * | 2019-09-11 | 2019-12-06 | 苏州大学 | 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用 |
| WO2022057904A1 (zh) * | 2020-09-18 | 2022-03-24 | 成都美杰赛尔生物科技有限公司 | 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤 |
| EP4052716A1 (en) * | 2021-03-04 | 2022-09-07 | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg | Cancer therapy involving car-engineered t-cells and parvovirus h-1 |
| WO2024054293A1 (en) * | 2022-09-08 | 2024-03-14 | Research Institute At Nationwide Children's Hospital | Oncolytic virus combination to maximize oncolytic activity |
| WO2024124190A1 (en) | 2022-12-09 | 2024-06-13 | Microbial Machines, Inc. | Engineered microorganisms for delivery of therapeutic agents |
| WO2024259195A1 (en) * | 2023-06-16 | 2024-12-19 | Elias Animal Health | Use of cd200ar-l for enhancing adoptive t-cell therapy |
| WO2024263805A1 (en) | 2023-06-21 | 2024-12-26 | Microbial Machines, Inc. | Genetically engineered microorganisms for detection of diseased cells |
| CN118045162A (zh) * | 2024-02-28 | 2024-05-17 | 北京景达生物科技有限公司 | 核心蛋白聚糖联合nk细胞在治疗实体瘤中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| EP2406387A4 (en) | 2009-03-09 | 2013-04-17 | Tvax Biomedical I Llc | CELL IMMUNOTHERAPY FOR INFECTION DISEASES |
| CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| EP3347473A4 (en) * | 2015-09-09 | 2019-04-10 | Tvax Biomedical I, LLC | METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY |
-
2016
- 2016-09-09 EP EP16845141.7A patent/EP3347473A4/en active Pending
- 2016-09-09 JP JP2018513549A patent/JP2018526428A/ja not_active Withdrawn
- 2016-09-09 WO PCT/US2016/050994 patent/WO2017044780A1/en not_active Ceased
- 2016-09-09 US US15/757,687 patent/US20190038727A1/en not_active Abandoned
-
2020
- 2020-07-27 US US16/939,266 patent/US11633442B2/en active Active
-
2021
- 2021-09-10 JP JP2021147640A patent/JP2022003043A/ja active Pending
-
2023
- 2023-04-05 US US18/295,994 patent/US12419924B2/en active Active
- 2023-10-12 JP JP2023176751A patent/JP2023176003A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526428A5 (enExample) | ||
| JP2023176003A5 (enExample) | ||
| JP2022092001A (ja) | 樹状細胞免疫療法 | |
| JP2022003043A (ja) | 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 | |
| CN107034235A (zh) | 联合靶向pd‑1及egfr的嵌合性抗原t细胞肿瘤免疫方法 | |
| Zhao et al. | Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response | |
| US12324836B2 (en) | Methods and compositions for vaccinating and boosting cancer patients | |
| US12370256B2 (en) | Activation of resident memory T cells for the treatment of cancer | |
| JP2015520129A (ja) | 多価乳がんワクチン | |
| WO2018137643A1 (zh) | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 | |
| CN107488235A (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| JP2008526763A (ja) | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 | |
| CN106554416A (zh) | 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用 | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| CN104262459A (zh) | 一种急性单核细胞白血病相关抗原mlaa-34 表位多肽及其疫苗和制药应用 | |
| CN116983406A (zh) | 人参皂苷脂质体用作肿瘤抗原的佐剂 | |
| TWI522112B (zh) | 疫苗佐劑、疫苗組合物與牛樟芝子實體之多醣體用於製備一疫苗佐劑的用途 | |
| Brown | Engaging pattern recognition receptors in solid tumors to generate systemic antitumor immunity | |
| CN111867619A (zh) | 过继性细胞治疗的先天寻靶 | |
| CN101072582B (zh) | 作为癌症疫苗佐剂的α胸腺肽 | |
| US20190255127A1 (en) | Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells | |
| CN117398456A (zh) | 一种特异性标记异源蛋白的肿瘤新抗原疫苗体系及其应用 | |
| CN101327317B (zh) | 一种治疗肿瘤的注射液及其制备方法 | |
| EA012072B1 (ru) | Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором, и их использование в лечении рака | |
| Mallmann | Tumor vaccination |